Work

1604MO Randomization to adjuvant nivolumab or ipilimumab + nivolumab based on pathological response to a single dose of neoadjuvant nivolumab in stage III melanoma

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.2232

Authors: J. Miura, A.K.S. Salama, X. Xu, G.M. Beasley, R. Al-Rohil, R. Brody, S. Mitnick, J. Tabita-Martinez, L. Giles, S. McGettigan, K. Kreider, A. Nandi, G. Wang, G. Mo, L. Schuchter, R. Amaravadi, A. Huang, P. Gimotty, G. Karakousis, T.C. Mitchell

Institutions: Abramson Cancer Center, University of Pennsylvania, Duke University, Duke Cancer Institute, University of North Carolina at Chapel Hill

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: University of Pennsylvania

OpenAlex ID: W4415941595

FWCI:

Cites:

Cited by:

Related to: 10